FDA Approval Summary: Pertuzumab for Adjuvant Treatment of HER2-Positive Early Breast Cancer
Lynn Howie(United States Food and Drug Administration), Julia A. Beaver(Center for Drug Evaluation and Research), Yasmin Choudhry(Center for Drug Evaluation and Research), Gideon M. Blumenthal(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jason Schroeder(United States Food and Drug Administration), Bellinda L. King‐Kallimanis(LUNGevity Foundation), Nancy S. Scher, Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Kirsten B. Goldberg(United States Food and Drug Administration), Rajeshwari Sridhara(Center for Drug Evaluation and Research), Lijun Zhang(Dalian Medical University), Amna Ibrahim(Beni-Suef University)
Cited by 68
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k